Stoke Therapeutics

Yahoo Finance • 3 days ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s pote... Full story

Yahoo Finance • 16 days ago

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results

Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies.... Full story

Yahoo Finance • 17 days ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –... Full story

Yahoo Finance • 17 days ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –... Full story

Yahoo Finance • 28 days ago

Implied JSMD Analyst Target Price: $92

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 2 months ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improveme... Full story

Yahoo Finance • 2 months ago

Stoke Therapeutics Names Ian Smith As CEO; Phase 3 Trial Of Zorevunersen Underway

(RTTNews) - Stoke Therapeutics, Inc. (STOK), on Monday, announced that it has appointed Ian Smith as Chief Executive Officer. Smith has served as Interim CEO since March 2025. Smith will continue to serve as a Director on the Company's Bo... Full story

Yahoo Finance • 3 months ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 3 months ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – – Substantial increase in seizure-free days and... Full story

Yahoo Finance • 4 months ago

Stoke Therapeutics stock hits 52-week high at $18.61

Stoke Therapeutics Inc (NASDAQ:STOK). stock reached a significant milestone, hitting a 52-week high of $18.61. According to InvestingPro data, the company’s impressive momentum includes a 36.81% gain in the past week alone, with the stock... Full story

Yahoo Finance • 4 months ago

Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome

Biogen (BIIB) and Stoke Therapeutics (STOK) said Monday they have dosed a first participant in a pha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental i... Full story

Yahoo Finance • 4 months ago

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most undervalued stocks. Biogen Inc. (NASDAQ:BIIB) is a global biotechnology leader known for its treatments in multiple sc... Full story

Yahoo Finance • 5 months ago

Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential

Investing.com - Jefferies initiated coverage on Stoke Therapeutics (NASDAQ:STOK), currently trading at $12.35 with a market capitalization of $674 million, with a Buy rating and a $30.00 price target. According to InvestingPro data, the co... Full story

Yahoo Finance • 6 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zor... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) (“Stoke”) on behalf of the company’s investors. Since July 2023, shares of Stoke’s common stock h... Full story

Yahoo Finance • 2 years ago

Investor Alert: Abbott Cooper PLLC Announces Investigation into Stoke Therapeutics, Inc.; Urges Stoke Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) (“Stoke” or the “Company”) on behalf of the Company’s investors. The subject of this investigation is to dete... Full story

Yahoo Finance • 3 years ago

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

– Company advancing second TANGO ASO into the clinic – – STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve disorder – BEDFORD, Mass., April 25, 20... Full story